# OnCo record paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021" ;
  schema:name "IPATential150: ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer"@en ;
  schema:description "Adding an AKT-blocking tablet to abiraterone delayed progression in the half of men who had lost PTEN, but at a considerable cost in side effects."@en ;
  schema:url <https://onco.cc/key-papers/paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(21)00580-8>, <https://pubmed.ncbi.nlm.nih.gov/34246347/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(21)00580-8> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Sweeney C, Bracarda S, Sternberg CN, et al." ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/histopathology-ihc/> ;
  onco:targets <https://onco.cc/targets/pten/>, <https://onco.cc/targets/akt/>, <https://onco.cc/targets/androgen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/ipatasertib/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/ar-signaling/> ;
  onco:terms <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/castration-resistance/> ;
  onco:journals <https://onco.cc/journals/lancet/> .